Form 4: Apellis General Counsel Reports Scheduled Stock Sale

Apellis Pharmaceuticals' General Counsel, David O. Watson, reported a scheduled sale of 5,000 shares of common stock at $25.22 per share.

Summary

• David O. Watson, General Counsel of Apellis Pharmaceuticals, Inc. (APLS), reported a transaction involving the company's common stock.
• The transaction was a sale of 5,000 shares of common stock.
• The shares were sold at a price of $25.22 per share.
• This sale was executed on October 16, 2025, as part of a pre-arranged 10b5-1 trading plan established on March 3, 2025.
• Following the transaction, Mr. Watson directly beneficially owns 113,730 shares of common stock.
• Additionally, Mr. Watson indirectly beneficially owns 10,000 shares through a custodial account for minor children and 50,136 shares through The David O. Watson Irrevocable Trust of 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, pre-scheduled insider transaction under a 10b5-1 plan, which typically does not reflect new information about the company's performance or outlook.

Positives

• The transaction was a scheduled sale under a Rule 10b5-1 trading plan, indicating a pre-planned personal financial management decision rather than a reaction to new company-specific information.

Negatives

• No specific negative implications for the company's operations or financial health are indicated by this routine insider transaction.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide information directly related to broader industry trends or competitive landscape.

Related Party Transactions

• Indirect beneficial ownership of 10,000 shares through a custodial account for minor children.
• Indirect beneficial ownership of 50,136 shares through The David O. Watson Irrevocable Trust of 2023, where the reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: This is a routine disclosure of an insider's pre-planned stock sale, which typically has minimal direct impact on other shareholders or the company's operations.

Key Dates

Recommendation

This Form 4 reports a pre-scheduled insider stock sale under a 10b5-1 plan. Such transactions are generally considered routine personal financial management and do not typically signal a change in the company's fundamental outlook or warrant a shift in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing does not provide new information to alter an existing investment thesis.

Keywords

Apellis Pharmaceuticals, APLS, Insider Transaction, Form 4, Stock Sale, David O. Watson, General Counsel, 10b5-1 Plan